Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICI trial: Eplerenone for chronic central serous chorio-retinopathy
2016-000113-70Phase 3Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Central Serous Chorioretinopathy (CSCR) comparing Eplerenone + usual care with Placebo + usual care (2 arms). Primary endpoint: Best-corrected visual acuity at 12 months. Started Jun 2020; status: completed.
02
Drugs
eplerenone
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on 2016-000113-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000113-70.